Reteplase, Recombinant Human tissue plasminogen activator
Recombinant Human tissue plasminogen activator(tPA), purified, glycosylated, 355 a.a. expressed in CHO cells. The product is genetically engineered to retain and delete certain portions of human tPA. The product is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. The product contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from the product - kringle-1, finger, and epidermal growth factor (EGF).
<0.001 EU per 1 μg of the protein by the LAL method
10.4 unit / vial
For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction.
Examples of Clinical Use:
Acute pulmonary emboli, intracoronary emboli and myocardial infarction
The product cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Mechanism of action:
Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
Reteplase is a recombinant human tissue plasminogen activator, which is a synthetic protein produced by gene recombination technology that is used to dissolve blood clots and facilitate the thrombotic process. It is mainly used to treat patients with acute myocardial infarction (AMI), which is myocardial ischemia caused by interruption of blood supply to the coronary artery. Through intravenous injection of Reteplase, it can rapidly activate the plasminase system and convert the body's fibrinolytic enzyme into the fibrinolytic enzyme, thus dissolving the thrombus and restoring the blood supply to the coronary artery. Reduce or avoid the further development of myocardial infarction. However, there are some potential risks and side effects associated with the use of Reteplase, for example, there may be a tendency to bleed, including internal and traumatic bleeding. Therefore, close monitoring and an individualized treatment plan are necessary before the use of Reteplase, and for patients with AMI, the physician will evaluate the potential risks and benefits on the basis of the specific situation of the patient and decide whether to use Reteplase for treatment.
2. Clinical application
Reteplase is mainly used in the treatment of patients with acute myocardial infarction (AMI). In addition to AMI, Reteplase has several other clinical applications, including: (1) Thrombotic stroke: Reteplase can be used to treat patients with certain types of thrombotic stroke, especially occlusion of middle cerebral artery branches caused by thrombotic occlusion. It can be recovered by dissolving the thrombus brain blood supply, in order to reduce the extent of the stroke and time window. (2) Deep vein thrombosis: to merge patients with deep vein thrombosis (DVT), sometimes using Reteplase for thrombolytic therapy. It helps to dissolve clots and restore the patency of veins. For these applications, the method of using Reteplase, dose, and course of treatment must be individualized according to the specific conditions of the patient and the guidance of the doctor. It should also be noted that the use of Reteplase may be accompanied by some potential risks and side effects, such as bleeding.
3. Advantages and Disadvantages
Reteplase, a recombinant human tissue plasminogen activator, is used for the treatment of thrombotic disorders such as acute myocardial infarction and thrombotic vascular occlusion. The following are the advantages and disadvantages of Reteplase in clinical applications: Advantages: (1) High efficiency: Reteplase can rapidly activate plasminogen and promote the dissolution of thrombus, thereby restoring blood flow and reducing the severity of thrombotic diseases such as myocardial infarction. (2) Ease of use: Reteplase can be administered intravenously, is easy to use, and can be quickly applied in the emergency room or other emergency situations. (3) Rapid onset: Reteplase has a rapid onset of action, which helps to quickly restore the blocked blood vessels and reduce the risk of myocardial infarction or other thrombosis-related diseases. Disadvantages: (1) Bleeding risk: Reteplase has thrombolytic properties, so it may increase the risk of bleeding during use. The application process requires close monitoring of patients with bleeding and coagulation function. (2) An allergic reaction: There are a few patients allergic to Reteplase, possible allergic reactions, such as skin rash, hives, breathing difficulties, etc. It should be avoided in patients with known hypersensitivity to Reteplase. (3) Drug cost: Reteplase is a high-cost drug, and its treatment costs are high. This may have limited use in some resource-poor areas or patients. The clinical application of Reteplase as a potent thrombolytic drug possesses the advantages of being fast effective, and easy to use, but also need to use caution to avoid the potential risk of bleeding and allergic reactions.
4. Research status
Currently, Reteplase and Recombinant Human tissue plasminogen activators are approved and widely used thrombolytic drugs. The main research work is related to its dose, use range, side effects, and other aspects. At the same time, in the pharmaceutical industry, there is also the development and promotion of new thrombolytic drugs. For example, tenecteplase is a new thrombolytic agent currently under study.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.